![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, February 17, 2022 7:15:23 PM
17 February, 2022 - 23:32 By Tony Quested
Cancer vaccine production starts in Cambridge.
A world first cancer vaccination has started production in Cambridge. US biotech pioneer Northwest Biotherapeutics (NW Bio) is steering the historic breakthrough by developing DCVax® personalised immune therapies for solid tumour cancers.
Business Weekly reported in early February that production was set to get underway at the company’s Sawston facility. Now it has.
NW Bio, headquartered in Maryland, is producing its first dendritic cell cancer vaccine for a compassionate use patient. A dendritic cell is a special type of immune cell found in tissues, such as the skin, and boosts immune responses by showing antigens on its surface to other cells of the immune system.
The production milestone follows approval by the UK Medicines and Healthcare Products Regulatory Agency of a licence for manufacture of GMP (clinical grade) cell therapy products at Sawston for compassionate use cases and approval by the Human Tissue Authority for NW Bio to collect and process human cells and tissues for medical purposes.
The MHRA licence was received in December following nearly two years of preparations. This included hiring and training of technical staff, preparation of approximately 1,000 regulatory documents, validation of facilities, equipment and protocols and practice manufacturing cycles. This was followed by a review and detailed inspection by the MHRA.
Since the licence was issued, Advent Bioservices – NW Bio’s contract manufacturer in the UK – has been conducting the required post-approval re-validations and testing so that the facility is now ready for the manufacture of cell therapy products for clinical use.
The first vaccine production for compassionate use treatment is for a glioblastoma patient. Glioblastoma is an aggressive cancer that originates in cells called astrocytes that support nerve cells. It can form in the brain or spinal cord. It is anticipated that Phase 1A of the Sawston facility will have the capacity to produce cancer vaccines for 450-500 patients per year.
NW Bio plans to continue developing the Sawston facility in phases, both to calibrate the capital expenditures with the capacity needed and to leave room for implementation of new technologies.
Northwest Biotherapeutics is focused on developing personalised immunotherapy products designed to treat cancers more effectively than current treatments – without toxicities of the kind associated with chemotherapies – and on a cost-effective basis, in both North America and Europe.
https://www.businessweekly.co.uk/news/biomedtech/cancer-vaccine-production-starts-cambridge
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM